• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Joe Jimenez's Aditum finds fresh twist on old idea, paying $10M for autoimmune BTK...

cafead

Administrator
Staff member
  • cafead   Apr 28, 2023 at 10:12: AM
via Joe Jimenez’s VC fund has ponied up $10 million to try to crack a nut that defeated a who’s who of top drug developers. The outlay gives the fund, Aditum Bio, near-global rights to a BTK inhibitor with a twist, which is in development in autoimmune diseases including rheumatoid arthritis.

article source
 

<